CenTrial Logo

Zavegepant Nasal Spray: A Promising Option for Acute Migraine Relief

by


Clinical trial shows zavegepant is effective in alleviating migraine symptoms

Migraine is a headache that can cause moderate to severe pain and other symptoms. Migraine attacks can last hours to days and significantly impact a person's quality of life. The effects of migraine can vary from person to person. Common effects include pulsating or throbbing pain, nausea, vomiting, sensitivity to light, sound, and smell, visual disturbances (aura) such as flashing lights and blind spots, irritation, and mood swings.

Migraine attacks can disrupt a person's daily activities, including work, school, and social life. The severe pain and associated symptoms can make concentrating, performing tasks, and engaging in everyday activities difficult. Migraine attacks may require rest and recovery time, impacting a person's productivity and ability to participate in their usual routine.

Migraines can have emotional and psychological effects on individuals. The chronic nature of migraine, with recurrent attacks, can cause anxiety, frustration, and depression. Migraine attacks can also disrupt sleep patterns, leading to fatigue and further impacting mood and emotional well-being.

Clinical Trial

A new treatment called zavegepant nasal spray was tested in a large trial to see if it could help with migraine attacks. The study involved adults with a history of moderate or severe migraine attacks at least twice a month. The participants were randomly assigned to receive either zavegepant nasal spray or a placebo and then treated for one migraine attack with the given therapy. The study was conducted at many medical centers across the USA and was double-blind, meaning neither the participants nor the doctors knew which treatment they were receiving.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Findings

The trial's main goal was to see if zavegepant could relieve pain and other bothersome symptoms of a migraine attack 2 hours after taking the treatment. The study found that more participants who used zavegepant had relief from pain and other symptoms than those who received the placebo. Zavegepant was also found to be safe and well-tolerated, with the most common side effects being changes in the sense of taste, nasal discomfort, and nausea. There were no signs of liver problems caused by zavegepant.

Conclusion

The researchers concluded that zavegepant nasal spray was effective in treating acute migraine attacks and was well-tolerated. However, more studies are needed to determine the long-term safety and effectiveness of zavegepant for treating migraines over time.
__________
National Library of Medicine, Mar-22-23
ClinicalTrials.gov NCT04571060





Share this article with a friend:
     


Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Whether you're healthy or have a medical condition you can participate in a clinical trial.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.


This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.